In cancer, IGF2BP2, a common m6A reader, exhibits aberrant expression, impacting the stability and expression of various mRNAs associated with oncogenes (e.g., MYC [43], KRAS [44], BCL2 [45]), metabolism-related genes (e.g., GLUT1 [46], HK2 [47]), stemness-related genes (e.g., SOX2 [48], NANOG [49], OCT4 [50]), and drug-resistance genes (e.g., ABCB1 [51], which encodes multidrug resistance proteins). Here, MYC is linked to cancer.